Market Cap
$590.6M
PHAT
Phathom Pharmaceuticals, Inc.
$6.92 ▼ -2.26%
Prev close $7.08Market cap$590.6M
ConsensusStrong Buy
12-mo target$20.45 (+195.6%)
▲ Bullish
Analyst conviction 9/10
High Impact Filing (7/10)13 New Institutional Positions14 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on PHAT right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (88%)
Inst. Holders
50 funds
Inst. Value
$416.8M
Inst. Activity
13 buys / 14 sells
SEC Reports
6
Press Releases
2
Price chart 30d -23.5%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 25, 2026 short_volume
Short Volume: PHAT — 66.0% short (0.4M / 0.6M)
Short: 424,612 | Exempt: 24,766 | TRF Vol: 643,815 | Short Ratio: 66.0% | Off-exchange volume (dark
Sep 3, 2026 Insider
Jul 30, 2026 SEC Breedlove Robert Charles surrendered for taxes 460 shares
Principal Accounting Officer @ $9.05 ($4.2K)
Phathom Pharmaceuticals reported Q2 2026 net revenue of $74.3M (up 88% YoY, beating consensus of $72.7M) and non-GAAP ad
8-K — Impact 5/10
Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above the $72.7M consensus, driven by strong VOQUEZNA pre
PRESS-RELEASE — Impact 6/10
Phathom Pharmaceuticals reported Q1 2026 EPS of -$0.37, missing consensus of -$0.10 by 289.5%, a significant earnings mi
PRESS-RELEASE — Impact 7/10
Jul 14, 2026 Insider
Breedlove Robert Charles surrendered for taxes 1,555 shares
Principal Accounting Officer @ $11.04 ($17.2K)
Jun 30, 2026 Inst.
GOLDMAN SACHS GROUP INC — DOUBLED
1,778,032 shares ($19.3M)
Jun 30, 2026 Inst.
Ensign Peak Advisors, Inc — TRIM
1,051,913 shares ($11.4M)
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
88% rate it Buy or better · 17 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 9, 2026 | Leerink Partners | INITIATE | Market Perform | 49% |
| Aug 17, 2026 | Barclays | MAINTAIN | Overweight | 54% |
| Jul 31, 2026 | Guggenheim | MAINTAIN | Buy | 52% |
| Jul 31, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| Jul 30, 2026 | Needham | MAINTAIN | Buy | 50% |
| Jun 17, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Aug 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Jul 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Jun 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| May 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Apr 1, 2026 | 6 | 9 | 2 | 0 | 0 | 88% | |
| Mar 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% | |
| Feb 1, 2026 | 6 | 8 | 3 | 0 | 0 | 82% |
Price targets
Where 11 covering analysts think PHAT trades over the next 12 months.
$20.45 +195.6% upside Strong Buy
Current$6.92 Low$10.00 Median$21.00 High$29.00 11 analysts
$10.00$29.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
6 SEC filing reports analyzed · 1 bullish, 2 bearish, 2 mixed, 1 neutral · avg impact 5.7/10.Plus 2 press releases.
MIXED8-K5/10
Phathom Pharmaceuticals reported Q2 2026 net revenue of $74.3M (up 88% YoY, beating consensus of $72
Jul 30, 2026
BEARISHPRESS-RELEASE6/10
Phathom reported Q2 2026 net revenue of $74.3M, up 88% YoY and above the $72.7M consensus, driven by
Jul 30, 2026
BEARISHPRESS-RELEASE7/10
Phathom Pharmaceuticals reported Q1 2026 EPS of -$0.37, missing consensus of -$0.10 by 289.5%, a sig
Jul 20, 2026
MIXEDPRESS-RELEASE5/10
Phathom reported Q1 2026 revenue of $58.3M (+104% YoY), beating the $56.8M consensus, but GAAP EPS o
Apr 30, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Sep 25, 2026
short_volume
Short Volume: PHAT — 66.0% short (0.4M / 0.6M)
Short: 424,612 | Exempt: 24,766 | TRF Vol: 643,815 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
Sep 17, 2026
short_volume
Short Volume: PHAT — 55.7% short (0.3M / 0.6M)
Short: 308,235 | Exempt: 3,800 | TRF Vol: 553,316 | Short Ratio: 55.7% | Off-exchange volume (dark pool + OTC)
Sep 1, 2026
other
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercial
Aug 20, 2026
short_volume
Short Volume: PHAT — 58.5% short (0.4M / 0.7M)
Short: 389,981 | Exempt: 87 | TRF Vol: 666,895 | Short Ratio: 58.5% | Off-exchange volume (dark pool + OTC)
Aug 13, 2026
ftd
FTD: PHAT — 102,636 shares ($0.9M) failed to deliver
Settlement: 20260813, Price: $9.17, FTD Value: $941,172.12, PHATHOM PHARMACEUTICALS INC CO
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.04 | $-0.01–$0.07 | 124.4% | -12.9% | 0↑ 2↓ | $0.1B | 5 |
| Next Q | $0.11 | $0.07–$0.15 | 236.2% | -10.7% | 0↑ 3↓ | $0.1B | 5 |
| Current FY | $-0.03 | $-0.11–$0.04 | 98.6% | -794.9% | 0↑ 1↓ | $0.3B | 5 |
| Next FY | $1.08 | $0.92–$1.51 | 3710.1% | -5.8% | 0↑ 3↓ | $0.5B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.037 | — |
| 7d ago | $0.036 | +0.001 |
| 30d ago | $0.042 | -0.005 |
| 60d ago | $0.049 | -0.013 |
| 90d ago | $0.049 | -0.013 |
Institutional ownership
Which big funds own PHAT (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $416.8M total value (38,417,761 shares) as of 2026-Q2. Top holders: BlackRock,, Invesco, Carlyle. Net selling activity: 14 institutions trimmed/exited vs 13 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 4,525,129 | $49.1M | 11.8% | — |
| Invesco Ltd. | 4,029,731 | $43.7M | 10.5% | — |
| Carlyle Group Inc. | 3,496,808 | $37.9M | 9.1% | — |
| MILLENNIUM MANAGEMENT LLC | 3,375,834 | $36.6M | 8.8% | ADD +93.2% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,656,944 | $28.8M | 6.9% | — |
| FRANKLIN RESOURCES INC | 1,970,828 | $21.4M | 5.1% | NEW |
| GOLDMAN SACHS GROUP INC | 1,778,032 | $19.3M | 4.6% | DOUBLED +183.9% |
| STATE STREET CORP | 1,586,323 | $17.2M | 4.1% | — |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 1,462,738 | $15.9M | 3.8% | NEW |
| GEODE CAPITAL MANAGEMENT, LLC | 1,315,687 | $14.3M | 3.4% | — |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| GOLDMAN SACHS GROUP INC | DOUBLED | 626,196 | 1,778,032 | +183.9% | $19.3M |
| Ensign Peak Advisors, Inc | TRIM | 1,627,806 | 1,051,913 | -35.4% | $11.4M |
| Point72 Asset Management, L.P. | NEW | — | 1,022,193 | — | $11.1M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 305,800 | 226,400 | -26.0% | $2.5M |
| UBS Group AG | TRIM | 360,371 | 204,573 | -43.2% | $2.2M |
| MORGAN STANLEY | DOUBLED | 76,681 | 199,909 | +160.7% | $2.2M |
| Jump Financial, LLC | DOUBLED | 26,445 | 191,866 | +625.5% | $2.1M |
| CITADEL ADVISORS LLC | TRIM | 383,058 | 184,901 | -51.7% | $2.0M |
| Trexquant Investment LP | TRIM | 293,305 | 173,884 | -40.7% | $1.9M |
| WELLS FARGO & COMPANY/MN | DOUBLED | 46,113 | 152,002 | +229.6% | $1.6M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
10 insiders, 21 transactions. Net $0.00 — $0.00 bought, $0.00 sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 3, 2026 | Breedlove Robert Charles | Principal Accounting Officer | TAX W/H | 460 | $9.05 | $4.2K |
| Jul 14, 2026 | Breedlove Robert Charles | Principal Accounting Officer | TAX W/H | 1,555 | $11.04 | $17.2K |
| May 22, 2026 | Parikh Asit | Director | GIFT | 28,000 | — | — |
| May 20, 2026 | Parikh Asit | Director | EXERCISE | 17,500 | $4.95 | $86.6K |
| May 20, 2026 | Parikh Asit | Director | D | 17,500 | — | — |
| May 19, 2026 | Parikh Asit | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | KARBE FRANK | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | Schroeder Theodore R | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | COLA MICHAEL F | Director | AWARD | 24,122 | — | — |
| May 19, 2026 | Topper James N | Director | AWARD | 24,122 | — | — |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for PHAT.
Shares short
10,157,209
Settlement Sep 15, 2026
Change vs prior
-6.2%
Semi-monthly cycle
Days to cover
9.1
At avg daily volume
Of shares outstanding
≈12.6%
Estimate — not % of float
All PHAT filing & press-release reports (8)
- 8-K reportJul 30, 2026
- PRESS-RELEASE reportJul 30, 2026
- PRESS-RELEASE reportJul 20, 2026
- PRESS-RELEASE reportMay 20, 2026
- PRESS-RELEASE reportMay 1, 2026
- PRESS-RELEASE reportApr 30, 2026
- DEFA14A reportApr 7, 2026
- 8-K reportFeb 26, 2026